Mikael Mazighi at #ESOC2026 presenting glenzocimab: a novel antibody targeting platelet GPVI, to inhibit #thrombus formation while potentially preserving haemostasis and limiting bleeding risk in acute ischaemic stroke.
@ESOstroke#Stroke#ClinicalTrials
The MILD-MT trial from China on the thrombectomy in mild strokes (low NIHSS) was successful
➡️ good assessment of mismatch
➡️ better 90-d. functional outcome
➡️ low initial NIHSS could lead to the further worsening, so still do TE
@ESOstroke#ESOC2026
Maarten Uyttenboogaart presenting at #ESOC2026 the results of CASES trial about the carotid artery stenting during endovascular treatment of acute ischemic stroke : the trial was non inferior and it is recommended to stent early
@ESOstroke
Dr. Amrou Sarraj presenting at @ESOstroke#ESOC2026 the results of ATLAS trial about thrombectomy (TE) in the large core ischemic stroke : earlier admission to TE, presence of mismatch showed an impressive NNT of 4 and an excellent functional outcome
@ESOstroke#ESOC2026
Dr. Yang Xiang in China about the efficacy of
alteplase prior to EVT
Among Chinese cohort alteplase was not superior to EVT alone, while EVT alone was noninferior to intravenous alteplase plus EVT
Dough Campbell from New Zealand presented a #MASTERSTROKE trial
2 groups were compared systolic 140 mm Hg and 170 and final mRS was looked up
No difference in primary outcome was observed
#ESOC2026
Pol Camps-Renom presented positive #HOPE trial on cerebral perfusion after TE data from 11 Spanish centers by rigorous BP control post intervention
Pts after #thrombectomy with TICI>2b compared to 2c and no intervention group #ESOC2026@ESOstroke
Bruce Campbell at #ESOC2026 talks about dornase. TNC breaks fibrin.
Dornase breaks extracellular DNA / NETs
Though the trial didn’t show significant results, further research is promising
Safety profile was excellent! @ESOstroke